Campbell & Co Investment Adviser’s Alexion Pharmaceuticals ALXN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,007	Closed	-$225K	–	507
2020 Q2	$225K	Buy	+2,007	New	+$213K	0.28%	181
2020 Q1	–	Sell	-5,850	Closed	-$633K	–	607
2019 Q4	$633K	Buy	5,850 +2,777	+90%	+$297K	0.19%	162
2019 Q3	$301K	Buy	3,073 +1,055	+52%	+$119K	0.11%	391
2019 Q2	$264K	Sell	2,018 -2,665	-57%	-$343K	0.12%	349
2019 Q1	$633K	Buy	+4,683	New	+$582K	0.31%	69
2018 Q3	–	Sell	-2,306	Closed	-$286K	–	571
2018 Q2	$286K	Buy	+2,306	New	+$270K	0.22%	208
2017 Q3	–	Sell	-3,348	Closed	-$407K	–	487
2017 Q2	$407K	Buy	+3,348	New	+$390K	0.38%	75
2015 Q1	–	Sell	-4,545	Closed	-$841K	–	302
2014 Q4	$841K	Buy	+4,545	New	+$842K	0.52%	73
2014 Q3	–	Sell	-15,681	Closed	-$2.45M	–	269
2014 Q2	$2.45M	Buy	+15,681	New	+$2.48M	0.98%	40

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's ALXN Position: Q3 2020 in Review

Campbell & Co Investment Adviser sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 2,007 shares — an estimated $225K sold.

Campbell & Co Investment Adviser first reported a position in ALXN in Q2 2014 and held it in 9 quarters. The position peaked at $2.45M in Q2 2014. 708 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Campbell & Co Investment Adviser reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Campbell & Co Investment Adviser sold 2,007 Alexion Pharmaceuticals shares in Q3 2020, an estimated $225K.
Campbell & Co Investment Adviser first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 9 quarters.
Campbell & Co Investment Adviser's Alexion Pharmaceuticals position peaked at $2.45M in Q2 2014.
708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2020, filed 15 Oct 2020.